Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase

Patients with melanoma brain metastases (MBM) have poor prognosis, albeit advances in locoregional and systemic treatments. The melanoma-specific Graded Prognostic Assessment (GPA) effectively stratifies survival for patients with MBM. Nevertheless, lactate dehydrogenase (LDH), a well known prognostic factor for patients with melanoma, is not represented in the GPA scores and might add prognostic information for patients with MBM. In this study, 150 consecutive patients with MBM were retrospectively analyzed with the aim of evaluating independent prognostic factors for MBM patients, including LDH. Furthermore, we implemented a disease-specific prognostic score and estimated survival according to treatment modalities. On the basis of multivariable Cox regression analyses, six prognostic factors (age, BRAF status, number of MBM, number of extracranial metastatic sites, performance status, and LDH level) resulted statistically significant in terms of survival and were combined in a prognostic score to stratify patients in distinct prognostic groups (P < 0.0001). Among treatment modalities, a multimodal approach with stereotactic radiosurgery or neurosurgery associated with systemic therapy showed the best outcome (median overall survival: 12.32 months, 95% confidence interval, 7.92-25.30). This is the first study to demonstrate that LDH has independent prognostic value for patients with MBM and might be used to improve prognostic stratification, albeit external validation is mandatory. Survival of patients with MBM is affected by both disease-specific risk factors and treatment modalities, with locoregional treatments associated with better outcomes.

[1]  R. Scolyer,et al.  Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). , 2021 .

[2]  M. Levivier,et al.  The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study , 2019, Journal of Neuro-Oncology.

[3]  M. Taphoorn,et al.  The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review , 2019, International journal of cancer.

[4]  R. Amaria,et al.  Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series , 2019, Cancer.

[5]  A. Hauschild,et al.  Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. , 2019, The New England journal of medicine.

[6]  A. Giobbie-Hurder,et al.  Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study , 2019, Melanoma research.

[7]  G. Tabatabai,et al.  Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. , 2019, Immunotherapy.

[8]  A. Law,et al.  Metastatic melanoma: Surgical treatment of brain metastases – Analysis of 110 patients , 2018, Journal of Clinical Neuroscience.

[9]  G. Long,et al.  Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy , 2018, Pigment cell & melanoma research.

[10]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[11]  Wen Jiang,et al.  Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). , 2017, International journal of radiation oncology, biology, physics.

[12]  Eudocia Q Lee,et al.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study , 2017, Neuro-oncology.

[13]  R. Braun,et al.  Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland , 2017, Melanoma research.

[14]  G. Long,et al.  Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. , 2017, European journal of cancer.

[15]  D. Schadendorf,et al.  Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. , 2016, The Lancet. Oncology.

[16]  L. Harrison,et al.  Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Michael L. Johnson,et al.  Regression coefficient-based scoring system should be used to assign weights to the risk index. , 2016, Journal of clinical epidemiology.

[18]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[19]  P. Queirolo,et al.  Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. , 2016, Cancer treatment reviews.

[20]  S. Danish,et al.  Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. , 2015, JAMA oncology.

[21]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[22]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[23]  A. Hauschild,et al.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[24]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[25]  P. Wen,et al.  Epidemiology of Brain Metastases , 2012, Current Oncology Reports.

[26]  K. Delman,et al.  The prognostic utility of LDH and disease-specific graded prognostic assessment for melanoma brain metastases. , 2011, Journal of Clinical Oncology.

[27]  P. Hwu,et al.  Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.

[28]  D. Schadendorf,et al.  Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma , 2011, Cancer.

[29]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Brown,et al.  Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. , 2009, International journal of radiation oncology, biology, physics.

[31]  Walter Curran,et al.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. , 2008, International journal of radiation oncology, biology, physics.

[32]  K. Shannon,et al.  Determinants of outcome in melanoma patients with cerebral metastases. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  David R. Anderson,et al.  Model selection and multimodel inference : a practical information-theoretic approach , 2003 .

[34]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[35]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[36]  E. Rakovitch,et al.  Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. , 2018, The Cochrane database of systematic reviews.